Just a Few Endos Account for Most Therapy Changes

According to pharma analytics firm SDI, 20% of endocrinologists who wrote prescriptions for oral diabetes therapies from September 2007 through August 2008 were responsible for 95% of new-to-brand prescriptions in that specialty; that is, new product starts, add-on therapy, or product switches.  This contrasts with primary care prescribers, among whom the top 30% were accountable for 90% of new-to-brand oral diabetes prescriptions.  Is it suprising that a relatively small percentage of physicians account for the bulk of new-to-brand prescriptions?


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s